Stuart is a Professor of Organic Chemistry at the University of Oxford, and the E. P. Abraham Cephalosporin Fellow in Organic Chemistry at St Hugh's College. He studied Chemistry with Medicinal Chemistry at the University of Warwick before undertaking PhD studies with Prof. David Jane and Prof. Jeff Watkins FRS in the Department of Pharmacology at the University of Bristol. Stuart completed post-doctoral studies with Prof. Andrew Holmes FRS at the University of Cambridge working on the synthesis of inositol polyphosphates. In 2003, he was appointed as a Lecturer in Bioorganic Chemistry at the University of St Andrews, in 2008 was appointed as an Associate Professor at Oxford, and in October 2014 he was promoted to Full Professor. In 2013 Stuart was a Visiting Associate at the California Institute of Technology, hosted by Prof. Bob Grubbs and Prof. Dianne Newman. Since 2016 he has been an Associate Editor for the Journal of Medicinal Chemistry and is on the Editorial Advisory Board for Organic Chemistry Frontiers. Stuart is the President of the RSC Organic Division. His research focuses on the development of molecular tools to enable the study of biological systems.
Akane holds a joint-appointment between University of Oxford and Newcastle University, where she is a chair and professor of Chemical Biology. After obtaining M.Chem and D.Phil degrees at Oxford, she spent three years in the biotech sector where she led a number of drug discovery projects across a wide range of therapeutic areas. In 2009 she returned to academia as a senior postdoctoral scientist and subsequently became a Principal Investigator in the Department of Chemistry and Radcliffe Department of Medicine at University of Oxford. She was awarded a British Heart Foundation Centre of Research Excellence (CRE) Senior Research Fellowship in 2012, a Royal Society Dorothy Hodgkin Fellowship in 2013 and an ERC Starting Grant in 2016. Akane is a director of GSK-Crick Chemical Biology CDT and a co-director of Chemistry in Cells CDT at University of Oxford. She is a committee member of the RSC Chemical Biology and Bio-Organic Chemistry Interest Group and an editorial board member of Communications Chemistry (Springer Nature Journal). Her group’s research focuses on understanding the chemistry of epigenetic regulation, chemical probes development, and (cyclic)peptide-based discovery and target validation.
Frances obtained her BSc from Imperial College London (Zoology) and her PhD from the University of Bath, UK. She was a post-doctoral fellow at Washington University Medical School in St. Louis, USA. She was a Lister Institute Senior Research Fellow and is currently Professor of Biochemistry and Pharmacology at the University of Oxford. Her main research interests include the biology and pathobiology of glycosphingolipids and lysosomal disorders. Her research led to the development of miglustat for the treatment of glycosphingolipid lysosomal storage diseases. Prof. Platt was awarded the Alan Gordon Memorial Award and the Horst Bickel Award for advances in metabolic disease therapy. She was elected a fellow of the Academy of Medical Sciences in 2011 and was the recipient of a Royal Society Wolfson Merit Award in 2013. In 2016 she became a Wellcome Trust Investigator in Science. She became Head of the Department of Pharmacology in 2020.
Angela is Professor of Medicinal Chemistry in the Departments of Chemistry and Pharmacology at the University of Oxford. In 2007 she was awarded a prestigious Research Councils’ UK Fellowship in Medicinal Chemistry jointly between the Department of Chemistry and Pharmacology. Her work lies at the interface of Chemistry, Biology and Medicine and aims to discover new small molecules and mechanisms to manipulate cell fate and translate them into therapeutic agents, particularly for degenerative diseases and cancer. Angela has realised several successful multidisciplinary research collaborations, including identifying small molecules to upregulate utrophin for the treatment of Duchenne muscular dystrophy, developing novel inhibitors and activators of developmental signaling pathways and new anti-cancer agents. In 2016, Angela was named as a ‘Rising Star’ in the ‘BioBeat 50 Movers and Shakers in BioBusiness’ report celebrating 50 outstanding women business leaders who are recognised for their contributions to global health innovation. In 2020 she was awarded a 2021 Harrington Rare Disease Scholar award in recognition of, and in support of, her work on developing a therapy for DMD.
Tracey joined the Conway group as Programme Manager to the EPSRC redOx⇌KCL and the Wellcome Trust Chemistry in Cells DPhil programmes in January 2020. Previously she was programme manager for OxStem-funded research programmes in the labs of Professor Angela Russell. Tracey joined the Department of Chemistry in 2013 as a project manager/administrator for the European-FP7-funded Innovative Doctoral Programme (IDP) entitled 'Oxford Innovative Organic Synthesis for Cancer Research (OxIOSCR)' with Professors Jeremy Robertson, Angela Russell, Tim Donohoe and David Hodgson. Previously she worked as a business planning consultant for new and young businesses and had established Communities in Business Ltd to deliver business education and training and to support community enterprises. Tracey completed her PhD in 2003 under the supervision of Professor Susan Brooks at Oxford Brookes University to elucidate the mechanisms underlying the aberrant synthesis of N-acetyl-galactosaminylated glycoproteins in metastatic breast cancer cells.
Kate joined Stuart's team in September 2020 and alongside supporting him as his PA, is responsible for the day to day administration of the Conway Group, the Wellcome Trust Chemistry in Cells DPhil programme and the EPSRC redOx⇌KCL programme grant. Prior to joining the Department of Chemistry, Kate worked at the Oxford Internet Institute as Professor Helen Margetts OBE’s Executive Assistant. Prior to that she was the Practice Manager at Figure Ground Consulting for 13 years. She has a degree in Art History and Anthropology from Oxford Brookes University.